
Optimizing the cost effectiveness of human papillomavirus (HPV) vaccination depends on several factors: the duration of vaccine immunity, achieving universal coverage in pre-adolescent girls, targeting catch-up vaccinations among young women and revising screening guidelines, according to a report published in the Aug. 21 issue of the New England Journal of Medicine.